螺内酯用于心血管不良结局高风险慢性血液透析患者(ALCHEMIST):多中心、双盲、随机、安慰剂对照试验及更新荟萃分析
ALCHEMIST是在法国、比利时和摩纳哥64家中心开展的多中心、双盲、随机、安慰剂对照、事件驱动试验,纳入≥18岁、慢性血液透析且至少有一种心血管合并症或危险因素的肾衰竭患者,经4周开放标签螺内酯25 mg隔日一次导入后,1:1随机至口服螺内酯滴定至25 mg每日一次或安慰剂。共644例随机(螺内酯320例、安慰剂324例),中位随访32.6个月,主要终点(心血管死亡、非致死性心肌梗死、急性冠脉综合征、卒中或心力衰竭住院)在螺内酯组78例(24%)发生、10.66/100患者年(95%CI 8.54-13.31),安慰剂组79例(24%)、10.70/100患者年(95%CI 8.59-13.35),HR 1.00(95%CI 0.73-1.36),p=0.98。血钾>6 mmol/L在螺内酯组135例(42%)、安慰剂组134例(41%),HR 1.12(95%CI 0.88-1.43)。更新荟萃分析显示盐皮质激素受体拮抗剂未降低全因死亡、心血管死亡或非致死性心血管事件,也未增加血钾>6 mmol/L事件的优势比。
要点
- 慢性血液透析且至少有一种心血管合并症或危险因素的患者中,螺内酯25 mg每日一次组主要心血管事件24%(10.66/100患者年)vs 安慰剂组24%(10.70/100患者年),HR 1.00(95%CI 0.73-1.36),p=0.98。
- 血钾>6 mmol/L在螺内酯组135例(42%)vs 安慰剂组134例(41%),HR 1.12(95%CI 0.88-1.43)。
- 更新荟萃分析显示盐皮质激素受体拮抗剂未降低全因死亡、心血管死亡或非致死性心血管事件,也未增加血钾>6 mmol/L事件的优势比。
- 作者认为,现有证据不支持在该人群超说明书使用螺内酯。
- 试验因申办方缺乏资金提前终止,中位随访32.6个月(IQR 17.3-48.4)。
适用人群与场景
- ≥18岁、慢性血液透析的肾衰竭患者,且至少有一种心血管合并症或危险因素。
- 研究在法国、比利时和摩纳哥的64家大学医院、综合医院及非营利或私立透析中心开展。
- 随机前需完成4周开放标签螺内酯25 mg隔日一次导入期。
诊断标准与关键阈值
- 主要终点为首次主要不良心血管事件时间,包括心血管死亡、非致死性心肌梗死、急性冠脉综合征、卒中或心力衰竭住院。
- 高钾血症定义为血钾>6 mmol/L。
处置流程与药物剂量
- 导入期:开放标签口服螺内酯25 mg隔日一次,持续4周。
- 随机后:口服螺内酯滴定至25 mg每日一次,或安慰剂。
研究设计与关键结果
- ALCHEMIST为研究者发起的多中心、双盲、随机、安慰剂对照、事件驱动试验,在法国、比利时和摩纳哥64家中心开展;1442例患者经本地筛查,823例纳入试验,794例进入导入期,644例随机(螺内酯320例、安慰剂324例);444例(69%)为男性,200例(31%)为女性。
- 试验因申办方缺乏资金提前终止;中位随访32.6个月(IQR 17.3-48.4)。
- 主要终点在螺内酯组78/320例(24%)发生,10.66/100患者年(95%CI 8.54-13.31);安慰剂组79/324例(24%)发生,10.70/100患者年(95%CI 8.59-13.35);HR 1.00(95%CI 0.73-1.36),p=0.98。
- 血钾>6 mmol/L在螺内酯组135例(42%)vs 安慰剂组134例(41%),HR 1.12(95%CI 0.88-1.43)。
- 更新荟萃分析显示盐皮质激素受体拮抗剂未降低全因死亡、心血管死亡或非致死性心血管事件,也未增加血钾>6 mmol/L事件的优势比。
证据类型、等级与局限
- 证据类型:多中心、双盲、随机、安慰剂对照、事件驱动试验,并更新荟萃分析双盲随机对照试验。
- 作者结论:在该人群螺内酯未减少主要心血管事件,现有证据不支持超说明书使用螺内酯。
- 局限:试验因申办方缺乏资金提前终止;中位随访32.6个月(IQR 17.3-48.4)。
对床旁实践的改变
- 作者认为,在慢性血液透析且心血管不良结局高风险的患者中,现有证据不支持超说明书使用螺内酯。
- 该人群中螺内酯25 mg每日一次未减少主要心血管事件,主要终点HR 1.00(95%CI 0.73-1.36)。
指南或共识出处
- ALCHEMIST试验,注册号ClinicalTrials.gov NCT01848639,由法国卫生部资助。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: No pharmacological therapy has been shown with certainty to improve the cardiovascular prognosis in patients with kidney failure on chronic haemodialysis. We aimed to investigate the effects of the steroidal mineralocorticoid receptor antagonist spironolactone on cardiovascular outcomes in patients on haemodialysis who are at high risk of cardiovascular events.
METHODS: ALCHEMIST was an investigator-initiated, multicentre, double-blind, randomised, placebo-controlled, event-driven trial conducted at 64 university hospitals, general hospitals, and non-profit or private practice dialysis centres in France, Belgium, and Monaco. Adult patients aged 18 years and older with kidney failure on chronic haemodialysis with at least one cardiovascular comorbidity or risk factor were enrolled into a 4-week run-in period on open-label oral spironolactone 25 mg every other day. Participants were randomly assigned (1:1) to oral spironolactone titrated to 25 mg per day or placebo. The randomisation sequence was computer generated and stratified by centre in blocks of 4 or 6, and permutation of treatments within each block. The random assignment was double-blinded. The primary endpoint was time to first major adverse cardiovascular event (cardiovascular death, non-fatal myocardial infarction, acute coronary syndrome, stroke, or hospitalisation for heart failure) and was analysed in the intention-to-treat population. We also performed an updated meta-analysis of double-blind, randomised controlled trials of mineralocorticoid receptor antagonists in patients on haemodialysis incorporating data from ALCHEMIST. The study was registered with ClinicalTrials.gov, NCT01848639.
FINDINGS: Between June 13, 2013, and Nov 24, 2020, 1442 patients were locally screened for eligibility. 823 patients were included in the trial and 794 entered the run-in period. 644 patients were randomly assigned to spironolactone (n=320) or placebo (n=324). 444 (69%) patients were men and 200 (31%) were women. The trial was stopped prematurely due to lack of funding from the sponsor. Median follow-up was 32·6 months (IQR 17·3-48·4). The primary endpoint occurred in 78 (24%) of 320 patients in the spironolactone group (10·66 per 100 patient-years [95% CI 8·54-13·31]) and 79 (24%) of 324 patients in the placebo group (10·70 per 100 patient-years [8·59-13·35]; hazard ratio [HR] 1·00 [95% CI 0·73-1·36]; p=0·98). Hyperkalaemia above 6 mmol/L was reported in 135 (42%) patients in the spironolactone group and 134 (41%) in the placebo group (HR 1·12 [95% CI 0·88-1·43]). In the meta-analysis, mineralocorticoid receptor antagonists did not reduce all-cause or cardiovascular mortality or non-fatal cardiovascular events and did not increase the odds of hyperkalaemia events (serum potassium concentration >6 mmol/L).
INTERPRETATION: In patients with kidney failure on haemodialysis and with high risk of adverse cardiovascular outcomes, spironolactone did not reduce the incidence of major cardiovascular events. The updated meta-analysis shows that mineralocorticoid receptor antagonists did not reduce all-cause or cardiovascular mortality. Therefore, off-label use of spironolactone in this setting is not supported by available evidence.
FUNDING: French Ministry of Health.
参考来源
- Rossignol P, Zannad F, Massy Z, et al. Spironolactone in patients on chronic haemodialysis at high risk of adverse cardiovascular outcomes (ALCHEMIST): a multicentre, double-blind, randomised, placebo-controlled trial and updated meta-analysis. Lancet. 2025. PMID: 40818851. doi:10.1016/S0140-6736(25)01194-8
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。